These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 33028759)

  • 21. The impact of in-hospital cardiac rehabilitation program on medication adherence and clinical outcomes in patients with acute myocardial infarction in the Lazio region of Italy.
    Soldati S; Di Martino M; Rosa AC; Fusco D; Davoli M; Mureddu GF
    BMC Cardiovasc Disord; 2021 Sep; 21(1):466. PubMed ID: 34565326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of pharmacist-initiated interventions in improving acute coronary syndrome secondary prevention pharmacotherapy prescribing upon discharge.
    Hassan Y; Kassab Y; Abd Aziz N; Akram H; Ismail O
    J Clin Pharm Ther; 2013 Apr; 38(2):97-100. PubMed ID: 23441979
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Practice patterns and trends in the use of medical therapy in patients undergoing percutaneous coronary intervention in Ontario.
    Garg P; Wijeysundera HC; Yun L; Cantor WJ; Ko DT
    J Am Heart Assoc; 2014 Aug; 3(4):. PubMed ID: 25122664
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal secondary prevention medication use in acute myocardial infarction patients with nonobstructive coronary artery disease is modified by management strategy: insights from the TRIUMPH Registry.
    Pitts R; Daugherty SL; Tang F; Jones P; Ho PM; Tsai TT; Spertus J; Maddox TM
    Clin Cardiol; 2017 Jun; 40(6):347-355. PubMed ID: 28387960
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Persistence with secondary prevention medications after acute myocardial infarction: Insights from the TRANSLATE-ACS study.
    Mathews R; Wang TY; Honeycutt E; Henry TD; Zettler M; Chang M; Fonarow GC; Peterson ED;
    Am Heart J; 2015 Jul; 170(1):62-9. PubMed ID: 26093865
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent Trends in Adherence to Secondary Prevention Guidelines for Patients Undergoing Coronary Revascularization in Washington State: An Analysis of the Clinical Outcomes Assessment Program (COAP) Registry.
    Riley RF; Don CW; Aldea GS; Mokadam NA; Probstfield J; Maynard C; Goss JR
    J Am Heart Assoc; 2012 Aug; 1(5):e002733. PubMed ID: 26600570
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Length of initial prescription at hospital discharge and long-term medication adherence for elderly patients with coronary artery disease: a population-level study.
    Ivers NM; Schwalm JD; Jackevicius CA; Guo H; Tu JV; Natarajan M
    Can J Cardiol; 2013 Nov; 29(11):1408-14. PubMed ID: 23816280
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [SECONDARY PREVENTION IN PATIENTS WITH ACUTE CORONARY SYNDROME HOSPITALIZED IN INTERNAL MEDICINE DEPARTMENTS].
    Yahia DH; Pereg D; Lishner M; Elis A
    Harefuah; 2015 May; 154(5):299-302, 339-40. PubMed ID: 26168639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Guideline-Directed Medical Therapy for Elderly Patients With Acute Myocardial Infarction Who Undergo Percutaneous Coronary Intervention　- Insights From a Retrospective Observational Study.
    Nishihira K; Nakai M; Kuriyama N; Kadooka K; Honda Y; Emori H; Yamamoto K; Nishino S; Kudo T; Ogata K; Kimura T; Kaikita K; Shibata Y
    Circ J; 2024 May; 88(6):931-937. PubMed ID: 38233147
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors associated with the use of evidence-based therapies after discharge among elderly patients with myocardial infarction.
    Austin PC; Tu JV; Ko DT; Alter DA
    CMAJ; 2008 Oct; 179(9):901-8. PubMed ID: 18936455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Secondary prevention of coronary artery disease in contemporary clinical practice.
    Jankowski P; Czarnecka D; Wolfshaut-Wolak R; Łysek R; Łukaszewska A; Bogacki P; Grodecki J; Mirek-Bryniarska E; Nessler J; Podolec P; Kawecka-Jaszcz K; Pająk A
    Cardiol J; 2015; 22(2):219-26. PubMed ID: 25299500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of age and chronic kidney disease on secondary prevention post-primary percutaneous coronary intervention.
    Zachariah D; Brown R; Kanagala P; Bashir A; Mohan M; Callan P; Rajendra R; Clark AL; Squire I; Gunning M; Lang CC; Kalra PR
    QJM; 2014 Mar; 107(3):185-92. PubMed ID: 24194563
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimizing prevention and guideline-concordant care in Montenegro.
    Knežević B; Musić L; Batrićević G; Bošković A; Bulatović N; Nenezić A; Vujović J; Kalezić M
    Int J Cardiol; 2016 Aug; 217 Suppl():S32-6. PubMed ID: 27381861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adherence Tradeoff to Multiple Preventive Therapies and All-Cause Mortality After Acute Myocardial Infarction.
    Korhonen MJ; Robinson JG; Annis IE; Hickson RP; Bell JS; Hartikainen J; Fang G
    J Am Coll Cardiol; 2017 Sep; 70(13):1543-1554. PubMed ID: 28935030
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of recommended medications after myocardial infarction in Austria.
    Winkelmayer WC; Bucsics AE; Schautzer A; Wieninger P; Pogantsch M;
    Eur J Epidemiol; 2008; 23(2):153-62. PubMed ID: 18064529
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Temporal trends, determinants, and impact of high-intensity statin prescriptions after percutaneous coronary intervention: Results from a large single-center prospective registry.
    Guedeney P; Baber U; Claessen B; Aquino M; Camaj A; Sorrentino S; Vogel B; Farhan S; Faggioni M; Chandrasekhar J; Kalkman DN; Kovacic JC; Sweeny J; Barman N; Moreno P; Vijay P; Shah S; Dangas G; Kini A; Sharma S; Mehran R
    Am Heart J; 2019 Jan; 207():10-18. PubMed ID: 30404046
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative Effectiveness of Angiotensin II Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors Following Contemporary Treatments in Patients with Acute Myocardial Infarction: Results from the Korean Working Group in Myocardial Infarction (KorMI) Registry.
    Song PS; Seol SH; Seo GW; Kim DK; Kim KH; Yang JH; Hahn JY; Gwon HC; Ahn Y; Jeong MH; Song YB; Kim DI;
    Am J Cardiovasc Drugs; 2015 Dec; 15(6):439-49. PubMed ID: 26153396
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of a P2Y12 Inhibitor Copayment Reduction Intervention With Persistence and Adherence With Other Secondary Prevention Medications: A Post Hoc Analysis of the ARTEMIS Cluster-Randomized Clinical Trial.
    Fanaroff AC; Peterson ED; Kaltenbach LA; Cannon CP; Choudhry NK; Henry TD; Anstrom KJ; Cohen DJ; Fonseca E; Khan ND; Fonarow GC; Wang TY
    JAMA Cardiol; 2020 Jan; 5(1):38-46. PubMed ID: 31721978
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trends in adherence to secondary prevention medications in elderly post-myocardial infarction patients.
    Choudhry NK; Setoguchi S; Levin R; Winkelmayer WC; Shrank WH
    Pharmacoepidemiol Drug Saf; 2008 Dec; 17(12):1189-96. PubMed ID: 18956426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of medications for secondary prevention after coronary bypass surgery compared with percutaneous coronary intervention.
    Hlatky MA; Solomon MD; Shilane D; Leong TK; Brindis R; Go AS
    J Am Coll Cardiol; 2013 Jan; 61(3):295-301. PubMed ID: 23246391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.